Dietary intervention to reduce obesity in Native American casino employees

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This intervention involves a randomized controlled trial aimed at reducing obesity and related diseases among Native American employees at Twin Arrows Casino. Participants will be assigned to either a micronutrient-dense plant-rich dietary intervention or a wait-list control group. The intervention includes 12 weeks of culturally relevant nutrition coaching led by trained Native American students from Northern Arizona University. Weekly group sessions will focus on improving dietary habits and overall wellness, with the goal of enhancing health outcomes in this underserved population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Self-identified Native American employee of Twin Arrows Casino;
* 21-65 years of age;
* self-reported body mass index (BMI) of \>24 kg/m;
* not currently participating in a weight-loss program;
* not taking any medications that could increase medical risk (e.g., insulin) or that had weight loss as a primary side effect;
* must work at Navajo Gaming Enterprise one year prior to the start of the study and indicate intent to work at Navajo Gaming Enterprise over the following year through the length of the study.

Exclusion Criteria:

* Individuals reporting gastric bypass, adjustable gastric band, gastric sleeve, or duodenal switch weight loss surgeries;
* pregnancy, or planning to become pregnant within the next year;
* insulin dependence;
* inability to attend weekly group coaching sessions will be ineligible to participate.

Where it's running

• PRANDIAL Lab
  Flagstaff, Arizona, United States Recruiting

Study contacts

• Principal investigator: Nanette Lopez, PhD, MS/MS — Northern Arizona University
• Study coordinator: Nanette Lopez, PhD, MS/MS
• Email: nanette.lopez@nau.edu
• Phone: 928-523-7913

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.